Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Comparative Trial of High-dose FARESTON for Aromatase Inhibitor resistant breast cancer compared to Faslodex

Next Previous
X
Search
Trial Profile

Randomized Comparative Trial of High-dose FARESTON for Aromatase Inhibitor resistant breast cancer compared to Faslodex

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Jan 2018

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Toremifene (Primary) ; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms HI-FAIR

    • Most Recent Events

    • 09 Dec 2017 Results presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 20 Sep 2015 Planned End Date changed from 31 Mar 2017 to 31 Mar 2016, as reported by University Hospital Medical Information Network - Japan record.
    • 20 Sep 2015 Status changed from recruiting to active, no longer recruiting, as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top